Ascendis Pharma A (ASND) EBIT Margin (2014 - 2026)

Ascendis Pharma A has disclosed EBIT Margin across 13 years of filings, most recently posting 10.06% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 10.06%, up 11329.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.59% (down 8550595.0% YoY), and the FY2025 annual result was 18.92%, up 4978.0% from the prior year.
• EBIT Margin came in at 10.06% for Q1 2026 at Ascendis Pharma A, up from 3.03% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 151717.42% in Q4 2024 to a low of 2303.46% in Q2 2022.
• The 5-year median for EBIT Margin is 167.28% (2024), against an average of 8483.71%.
• Across the five-year window, EBIT Margin surged 15173248 bps in 2024 and sank 15171439 bps in 2025, its largest moves.
• Ascendis Pharma A's EBIT Margin stood at 643.75% in 2022, then surged by 98 bps to 15.07% in 2023, then jumped by 1007137 bps to 151717.42% in 2024, then slumped by 100 bps to 3.03% in 2025, then jumped by 232 bps to 10.06% in 2026.
• The last three EBIT Margin figures came in at 10.06% (Q1 2026), 3.03% (Q4 2025), and 5.15% (Q3 2025), per Business Quant data.